| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_43a72884e25aaecffebe0942132d704f
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_f8801100963f527f1ec95ac6df58708e
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_4ce42c7457049ab68bad501e0c4708f6 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-50
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-565
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-56
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-73
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2333-575
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-505 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2869
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P15-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-574
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-28 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K17-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K17-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-395
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12P21-08 |
| filingDate |
2007-10-31-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
2012-10-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_aa3b91111e3610c3562e43f3b2cd70c3
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_aa373f7657dc1b04bce1ae7f9b4ce200 |
| publicationDate |
2012-10-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-8278423-B2 |
| titleOfInvention |
Monoclonal antibodies and fragment thereof directed against the human Anti-Müllerian Hormone type II receptor (AMHR-II) |
| abstract |
The present invention relates to monoclonal antibodies and fragment thereof directed against the human Anti-Müllerian Hormone type II receptor (AMHR-II) and their use for treating and diagnosing cancer diseases, such as ovarian cancers. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10509035-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2013164300-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9458239-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2021043849-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-3789401-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2018189381-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2018189379-A1 |
| priorityDate |
2006-11-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |